

Minimally invasive pancreatoduodenectomy is associated with lower morbidity compared to open pancreatoduodenectomy

An updated meta-analysis of randomized controlled trials and high-quality nonrandomized studies

Jia-fei Yan, MD, Yu Pan, MD, Ke Chen, MD, He-pan Zhu, MD, Qi-long Chen, MD*

Abstract

Background: Minimally invasive pancreatoduodenectomy (MIPD) is being increasingly performed as an alternative to open pancreatoduodenectomy (OPD) in selected patients. Our study aimed to present a meta-analysis of the high-quality studies conducted that compared MIPD to OPD performed for pancreatic head and periampullary diseases.

Methods: A systematic review of the available literature was performed to identify those studies conducted that compared MIPD to OPD. Here, all randomized controlled trials identified were included, while the selection of high-quality, nonrandomized comparative studies were based on a validated tool (i.e., Methodological Index for Nonrandomized Studies). Intraoperative outcomes, postoperative recovery, oncologic clearance, and postoperative complications were also evaluated.

Results: Sixteen studies matched the selection criteria, including a total of 3168 patients (32.1% MIPD, 67.9% OPD). The pooled data showed that MIPD was associated with a longer operative time (weighted mean difference [WMD]=80.89 minutes, 95% confidence interval [CI]: 39.74-122.05, P < .01), less blood loss (WMD=-227.62 mL, 95% CI: -305.48 to -149.75, P < .01), shorter hospital stay (WMD=-4.68 days, 95% CI: -5.52 to -3.84, P < .01), and an increase in retrieved lymph nodes (WMD=1.85, 95% CI: 1.33-2.37, P < .01). Furthermore, the overall morbidity was significantly lower in the MIPD group (OR=0.67, 95% CI: 0.54-0.82, P < .01), as were total postoperative pancreatic fistula (POPF) (OR=0.79, 95% CI: 0.63-0.99, P = .04), delayed gastric emptying (DGE) (OR=0.71, 95% CI: 0.52-0.96, P = .02), and wound infection (OR=0.56, 95% CI: 0.39-0.79, P < .01). However, there were no statistically significant differences observed in major complications, clinically significant POPFs, reoperation rate, and mortality.

Conclusion: Our study suggests that MIPD is a safe alternative to OPD, as it is associated with less blood loss and better postoperative recovery in terms of the overall postoperative complications as well as POPF, DGE, and wound infection. Methodologic high-quality comparative studies are required for further evaluation.

Abbreviations: CI = confidence interval, DGE = delayed gastric emptying, ISGPF = International Study Group for Pancreatic Fistula, ITT = intention-to-treat, LPD = laparoscopic pancreatoduodenectomy, MINORS = Methodological Index for Nonrandomized Studies, MIPD = minimally invasive pancreatoduodenectomy, NRCT = nonrandomized comparative trial, OPD = open pancreatoduodenectomy, OR = odds ratio, PD = pancreatoduodenectomy, POPF = postoperative pancreatic fistula, PPH = postpancreatectomy hemorrhage, RCT = randomized controlled trial, RLNs = retrieved lymph nodes, RPD = robot-assisted pancreatoduodenectomy, SD = standard deviation, WMD = weighted mean difference.

Keywords: high quality, laparoscopy, meta-analysis, minimally invasive, morbidity, pancreaticoduodenectomy, robot

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

Medicine (2019) 98:32(e16730)

Received: 26 February 2019 / Received in final form: 9 July 2019 / Accepted: 15 July 2019

http://dx.doi.org/10.1097/MD.000000000016730

Editor: Emmanuel Melloul.

JY and YP contributed equally to this work.

This research was supported by Education Department project of Zhejiang Province (grant no: Y201326835).

Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.

^{*} Correspondence: Qi-long Chen, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou 310016, Zhejiang, China (e-mail: faithchen@zju.edu.cn).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Pancreatoduodenectomy (PD) is one of the most complex procedures performed in the field of abdominal surgery, though the number of these procedures being performed has been on the rise in recent years due to the improved diagnostic capabilities, expanding indications, and formal development of pancreatic surgery training. However, despite advances in patient selection, surgical techniques, and postoperative care, morbidity still occurs in up to 40% of patients undergoing open pancreatoduodenectomy (OPD).^[1]

Contrastingly, minimally invasive surgery (MIS) has been the main direction established in terms of surgical development in the 21st century.^[2] Researchers have demonstrated how MIS could be used to achieve catabatic pain, reduced morbidity, shorter hospital stays, and a rapid return to baseline performance status, with oncologic equivalent outcomes when compared to the traditional open surgery procedures, [3-5] and therefore, the selection of MIS has become the professional choice of pursuit for surgeons, as well as the preferred treatment option for patients.^[6] With respect to pancreatic surgery, however, the development of minimally invasive pancreatoduodenectomy (MIPD) lags considerably behind that of minimally invasive distal pancreatectomy, as the latter represents a lessdemanding technique without any reconstruction, whereas the former is technically demanding and should be performed only in referral centers by experienced hands. Over the past few years, the advancements in relevant devices and gained experience have gradually expanded the indications of MIPD, resulting in several centers reporting promising outcomes after MIPD was performed,^[/] yet the controversies and concerns regarding MIPD vs OPD still remain, which has led some researchers to address these issues objectively in the form of meta-analyses.^[8-12] However, in these studies, conflicting results have been found between published metaanalyses with respect to morbidity, mortality, retrieved lymph nodes (RLNs), and surgical margins. Additionally, as randomized controlled trials (RCTs) published on this topic are scarce, these meta-analyses further include all nonrandomized controlled trials (NRCTs) available to pool the outcomes together. On the one hand, however, poor-quality NRCTs may have exaggerated the effect magnitude of an intervention, either by their intrinsic flaws or external factors such as publication bias, and therefore, metaanalyses based on such studies have not been adequate to examine the advantages and disadvantages of this emerging technique. On the other hand, there has also been evidence that the estimates derived from high-quality NRCTs may be similar to those derived from RCTs.^[13] Therefore, we designed an updated study by pooling the data from all of the available RCTs and high-quality NRCTs published to date, to evaluate the safety and efficacy of MIPD as an acceptable alternative to OPD.

2. Materials and methods

Our current meta-analysis was undertaken in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.^[14] This study did not require ethical approval as it was a review of the existing published literature and did not involve the handling of individual patient data.

2.1. Literature search

A PubMed, Embase, and Google Scholar database search were each performed to identify all published comparative studies available that analyzed and compared MIPD to OPD. Keywords included the terms "minimally invasive," "laparoscopic," "robotic," "Da Vinci," "pancreaticoduodenectomy," "Whipple," "PD," and "pancreatic resection," with the search restricted to human studies published only between January 1994 and January 2019. Furthermore, MIPD here included both laparoscopic pancreatoduodenectomy (LPD) and robot-assisted pancreatoduodenectomy (RPD) data. References from relevant articles and reviews were manually searched for, while the language of publication was confined to English.

2.2. Quality assessment

Checklists were used by reviewers for data extraction and assessment of the methodologic quality, with the methodologic quality of the eligible RCTs assessed by the Jadad scale, which included all RCTs in the analysis, and that of the NRCTs assessed by the Methodological Index for Nonrandomized Studies (MINORS),^[15] a tool developed by a group of practicing surgeons in France and validated specifically for such NRCT evaluations. Certain modifications were introduced to the MINORS to meet the needs of our study, which have been listed in Supplementary Table 1, http://links.lww.com/MD/D158. In total, 8 items were evaluated, each with a maximum score of 16 points, the studies with 12 or more points were considered to be high quality and were included in our meta-analysis, while those with <12 points were considered poor quality and were excluded.

2.3. Data extraction

Two investigators independently tabulated the extracted data and a double-check procedure was also performed to ensure its accuracy, following which a manager subsequently inputted the data into a spreadsheet. Duplications in the data were identified by matching both the authors' names and publication center, and any overlaps between authors or centers were resolved by selecting the higher quality or more recent literature published by them.

2.4. Variables and endpoints

Basic demographics: 1st author, publication year, and total number of patients in both groups.

Intraoperative parameters: operative time, estimated blood loss, and blood transfusion rate.

Postoperative parameters: length of hospital stay, morbidity, postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), postpancreatectomy hemorrhage (PPH), wound infection, reoperation rate, and mortality.

Oncologic clearance: RLNs and surgical margins.

The intention-to-treat (ITT) analysis was investigated, with POPF, DGE, and PPH diagnosed in accordance with the International Study Group for Pancreatic Fistula (ISGPF) criteria.^[16–18] In our study, a clinically significant POPF was defined as ISGPF grade B/C.^[16] Moreover, the Clavien-Dindo classification for postoperative morbidity was also checked,^[19] in which the major complications were established as grades III to V.

2.5. Statistical analysis

Statistical analyses were performed using odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous variables

and weighted mean differences (WMDs) with 95% CIs for continuous variables. The statistical mean and standard deviations, medians and ranges, or interquartile ranges were not estimated as described by Hozo et al,^[20] as this method may have led to a deviation from the true value, especially if the sample size was small or the samples exhibited significant skewness. Moreover, the heterogeneity among studies was assessed using a Chi-squared test-based Q-statistic and was considered statistically significant for P < .10, while the effect of heterogeneity was quantified using $I^2 = 100\% \times (Q - df)/Q$, with the I^2 ranges between 0% and 100% and the I^2 values of 25%, 50%, and 75% defined as low, moderate, and high estimates, respectively. If data were not significantly heterogeneous (P > .05 or $I^2 < 50\%$), the pooled effects were calculated using a fixed model, in contrast to the significantly heterogeneous data, for which a random model was used. Furthermore, a subgroup analysis that categorized MIPD into LPD and RPD was also conducted to determine the accurate advantages and consistency of both the procedures. Lastly, any potential publication bias was determined by conducting an informal visual inspection of the funnel plots. The RevMan 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was implemented for the statistical analyses in our study, with a 2-tailed value of P < .05 being considered significant.

3. Results

3.1. Studies selected and quality assessment

Data extraction from the various electronic databases yielded an initial total of 696 abstracts. After the exclusion of nonrelevant citations, 48 potentially relevant citations remained for full-text screening, which included 1 RCT and 47 NRCTs, all published between 2009 and 2018. Twenty-seven of these NRCTs were then excluded after our quality assessment was performed, due to MINORS scores of <12,^[21-47] followed by 5 more NRCTs, which contained data that overlapped with data from other included studies.^[48-52] Thus, 1 RCT^[53] and 15 NRCTs were finally included in the present study.^[54-68] A flowchart of the aforementioned literature search strategies is shown in Figure 1. The single RCT received a Jadad score of 3.^[53] The assessment of the NRCTs is summarized in Table 1. Generally, the poor-quality NRCTs suffered from methodologic drawbacks frequently seen in retrospective designs, incomplete outcomes reports, and perioperative clinical mismanagement. The major features of the studies included in the meta-analysis are summarized in Table 2. A total of 3168 patients were included in the analysis, of which 1018 (32.1%) underwent MIPD and the remaining 2150 (67.9%) underwent OPD. With respect to the MIPD approach taken, 10 studies were reported as performing LPD,^[53,54,57,58,60,61,63,65,67,68] whereas another 6 performed RPD.^[55,56,59,62,64,66]



Figure 1. Flow chart of literature search strategies.

Table 1

Modified Met	hodological Ir	ndex for Nonra	andomized Stu	udy score of i	nitial eligible n	onrandomized	d comparative	studies.	
Author	1	2	3	(4)	5	6	$\overline{\mathcal{O}}$	8	Score
Cho	2	2	1	0	2	2	1	0	10
Zhou	2	1	1	1	2	2	1	0	10
Zureikat	2	2	2	0	2	0	2	0	10
Buchs	2	2	2	0	2	0	1	2	11
Kuroki	2	1	1	0	2	2	1	0	9
Lai	2	1	1	0	2	1	1	0	8
Asbun	2	2	2	0	2	1	1	2	12
Chalikonda	2	2	1	1	2	2	2	1	13
Lei	2	1	1	0	2	2	1	0	9
Mesleh	2	2	1	0	2	2	2	2	13
Croome	2	2	1	1	2	2	1	2	13
Speicher	2	1	1	0	2	2	1	1	10
Wang	2	2	2	0	2	2	1	0	11
Hakeem	2	1	1	0	2	2	2	0	10
Bao	2	1	2	1	2	2	1	1	12
Wellner	2	2	2	1	2	1	2	2	14
Langan	2	2	1	0	2	2	1	1	11
Song	2	1	2	2	2	2	1	2	14
Adam	2	1	1	0	2	2	1	2	11
Tee	2	2	2	0	2	2	1	2	13
Dokmak	2	2	1	0	2	2	2	2	13
Sharne	2	1	1	0	2	2	1	2	11
Croome	2	1	1	0	2	2	1	1	10
Mendoza	2	2	1	1	2	2	1	0	10
Liang	2	2	1	0	2	2	1	0	10
Chen	2	2	2	1	2	2	2	2	15
Tan	2	1	1	1	2	2	2	1	10
Zureikat	2	1	1	0	2	2	2	2	12
Nusshaum	2	1	1	0	2	2	1	2	11
Raker	2	1	2	0	2	2	1	1	11
Delitto	2	2	ے 1	0	2	2	1	2	10
Tran	2	ے 1	1	0	2	ے 1	1	2	10
Roggi	2	1 2	1	0	2	1	1	2	10
Doyyi Kantar	2	ے 1	1	0	2	2	ے 1	2	10
Giraie	2	1 2	1	0	2	2	1	2	12
MeMillen	2	ے 1	1	0	2	ے 1	2	2	10
Povos	2	1	1	0	2	1	2	2	10
FUVES Stouffor	2	1	1	0	2	2	∠ 1	0	10
Coprod	2	1	1	0	2	0	1	۲ ۲	9
Conrad	2	2	1	0	2	1	2	1	11
Khaleo	2	2	1	1	2	1	2	0	11
KIIII	2	2		1	2	2	1	2	13
Chapman	2	2	2	0	2	2	2	1	13
Napoli Mana	2	2	2	U	2	2	1	2	13
ivieng	2	2	1	U	2	2	2	2	13
Chapman	2	1	1	0	2	2	1	2	11
Chen	2	1	1	1	2	2	2	2	13
Kantor	2	1	1	0	2	2	1	2	11

(1) = consecutive patients, (2) = prospective data collection, (3) = reported endpoints, (4) = unbiased outcome evaluation, (5) = appropriate controls, (6) = contemporary groups, (7) = groups equivalent, (8) = sample size.

3.2. Meta-analysis

All eligible parameters were pooled for the meta-analysis. The results of this are listed in Table 3.

3.2.1. Intraoperative effects. The pooled data showed that MIPD was associated with a longer operative time (WMD= 80.89 minutes, 95% CI: 39.74-122.05, P < .01), less blood loss (WMD=-227.62 mL, 95% CI: -305.48 to -149.75, P < .01), and lower transfusion rates (OR=0.69, 95% CI: 0.54-0.89, P < .01). Additionally, statistically significant results with respect to between-study heterogeneity were identified in terms of the

operative time $(I^2=97\%, P<.01)$ and blood loss $(I^2=95\%, P<.01)$, but not the transfusion rate $(I^2=29\%, P=.18)$.

3.2.2. Postoperative clinical course. The pooled data further showed a shorter length of hospital stay with respect to MIPD (WMD = -4.68 days, 95% CI: -5.52 to -3.84, P < .01) without significant heterogeneity ($I^2 = 0\%$, P = .64), and furthermore, the pooled analysis indicated that the rate of overall morbidity was significantly lower in the MIPD group (OR = 0.67, 95% CI: 0.54-0.82, P < .01) with moderate heterogeneity ($I^2 = 44\%$, P = .04) (Fig. 2). Contrarily, our analysis revealed that there was no

Table 2 Summary of studies included in the meta-analysis

					Sampl	e size					
Author	Region	Year	Study period	MIA	MIPD	OPD	ITT	ISGPF	Clavien–Dindo	Mortality	Management of pancreatic stump
Asbun	USA	2012	2005–2011	L	53	215	No	Yes	Yes	100 d	In, PJ: DTM
Chalikonda	USA	2012	2009-2010	R	30	30	Yes	Yes	N/A	30d	In, PJ: DTM
Croome	USA	2014	2008-2013	L	108	214	Yes	Yes	Yes	30d	In, PJ: DTM
Bao	USA	2014	2009-2011	R	28	28	Yes	Yes	N/A	90d	In, PJ: DTM
Wellner	Germany	2014	2010-2013	L	40	40	Yes	Yes	Yes	30d	Ex, PG
Song	Korea	2015	2007-2012	L	97	198	No	Yes	Yes	30d	In, PJ: DTM or dunking
Dokmak	France	2015	2011-2014	L	46	46	Yes	Yes	Yes	90d	In, 1 layer, PJ
Chen S	China	2015	2010-2013	R	60	120	Yes	Yes	Yes	N/A	In, PJ: DTM
Zureikat	USA	2016	2011-2015	R	211	817	No	Yes	Yes	90d	N/A
Delitto	USA	2016	2010-2014	L	52	50	Yes	Yes	Yes	30d	In, PJ: DTM
Boggi	Italy	2016	2008-2014	R	83	36	N/A	Yes	Yes	30d/90d	In, PJ: DTM
Palanivelu	India	2017	2013-2015	L	32	32	Yes	Yes	Yes	90d	In, PJ: dunking or MTM
Kim	Korea	2018	2015-2017	R	51	186	N/A	Yes	Yes	30d	N/A

N/A DTM = duct-to-mucosa, Ex = extracorporeally, In = intracorporeally, ISGPF = international study group of pancreatic fistula, ITT = intention-to-treat, L = laparoscopy, MIA = minimally invasive approach, MTM = mucosa-to-mucosa, N/A = not applicable, O = open, PD = pancreatoduodenectomy, PG = pancreaticogastrostomy, PJ = pancreaticojejunostomy.

Yes

N/A

Yes

Yes

Yes

N/A

Yes

Yes

Table 3

Chapman

Chen XM

Meng

Results of the meta-analysis.

USA

China

China

2018

2018

2018

2012-2016

2010-2015

2013-2017

L

L

L

22

58

47

25

58

55

		Samp	le size					
Outcomes	No. studies	MIPD	OPD	Heterogeneity (P, I ²)	Model	OR/WMD	95% CI	P-value
Operation time, min	8	532	912	<.01, 97%	R	80.89	39.74-122.05	<.01
LPD vs OPD	6	389	756	<.01, 98%	R	76.87	27.08-126.66	.01
RPD vs OPD	2	143	156	.60, 0%	R	91.28	66.18-116.38	<.01
Blood loss, mL	7	440	950	<.01, 95%	R	-227.62	-305.48 to -149.75	<.01
LPD vs OPD	6	389	764	<.01, 96%	R	-261.91	-345.38 to -178.45	<.01
RPD vs OPD	1	51	186	-	 Not 	applicable		-
Transfusion	10	718	1441	.18, 29%	F	0.69	0.54-0.89	<.01
LPD vs OPD	6	336	440	.12, 43%	F	0.56	0.38-0.83	<.01
RPD vs OPD	4	382	1001	.49, 0%	F	0.80	0.58-1.11	.18
Hospital stay, d	6	360	824	.64, 0%	F	-4.68	-5.52 to -3.84	<.01
LPD vs OPD	4	249	518	.34, 11%	F	-4.64	-5.57 to -3.71	<.01
RPD vs OPD	2	111	306	.88, 0%	F	-4.84	-6.75 to -2.94	<.01
Morbidity	14	749	1277	.04, 44%	R	0.67	0.54-0.82	<.01
LPD vs OPD	9	497	875	.02, 55%	R	0.67	0.52-0.85	<.01
RPD vs OPD	5	252	402	.23, 28%	R	0.66	0.41-1.07	.10
Major complications	12	887	1881	.69, 0%	F	0.96	0.76-1.20	.70
LPD vs OPD	9	533	908	.52, 0%	F	0.90	0.65-1.23	.50
RPD vs OPD	5	252	402	.23, 28%	F	0.67	0.45-0.99	.90
POPF	14	756	1147	.35, 0.9%	F	0.79	0.63-0.99	.04
LPD vs OPD	10	555	933	.58, 0%	F	0.76	0.58-0.98	.04
RPD vs OPD	4	201	214	.09, 54%	F	0.91	0.56-1.48	.70
Significant POPF	16	1018	2150	.36, 8%	F	1.02	0.81-1.30	.85
LPD vs OPD	10	555	933	.69, 0%	F	0.88	0.63-1.23	.45
RPD vs OPD	6	463	1217	.15, 38%	F	1.22	0.86-1.72	.27
DGE	14	755	1373	.97, 0%	F	0.71	0.52-0.96	.02
LPD vs OPD	9	503	883	.66, 0%	F	0.64	0.47-0.95	.03
RPD vs OPD	5	252	490	1.00, 0%	F	0.89	0.51-1.56	.68
PPH	9	496	830	.73, 0%	F	1.41	0.92-2.15	.11
LPD vs OPD	7	384	660	.59, 0%	F	1.49	0.93-2.40	.10
RPD vs OPD	2	112	170	.52, 0%	F	1.14	0.45-2.87	.78
Wound infection	9	558	1530	.46, 4%	F	0.56	0.39-0.79	<.01
LPD vs OPD	5	206	377	.96, 0%	F	0.38	0.22-0.67	<.01
RPD vs OPD	4	352	1153	.32, 14%	F	0.70	0.46-1.09	.12
Reoperation	9	429	605	.65, 0%	F	1.10	0.70-1.72	.69

(continued)

In, PJ: DTM

In, PJ: DTM

In, PJ: DTM

90d

30d

N/A

(continueu).								
		Samp	le size					
Outcomes	No. studies	MIPD	OPD	Heterogeneity (<i>P</i> , <i>f</i>)	Model	OR/WMD	95% CI	P-value
LPD vs OPD	5	228	391	.60, 0%	F	1.40	0.78-2.52	.26
RPD vs OPD	4	201	214	.65, 0%	F	0.77	0.38-1.57	.48
Mortality	14	949	2070	.95, 0%	F	0.99	0.59-1.68	.98
LPD vs OPD	8	486	853	.83, 0%	F	1.04	0.50-2.20	.91
RPD vs OPD	6	463	1217	.81, 0%	F	0.95	0.45-1.98	.89
Retrieved lymph nodes	7	308	791	.12, 36	F	1.85	1.33-2.37	<.01
LPD vs OPD	6	289	753	.12, 42	F	1.88	1.35-2.41	<.01
RPD vs OPD	1	19	38	-	 Not 	applicable		_
R0 rate	13	550	1361	<.01, 63%	R	1.43	0.78-2.63	.25
LPD vs OPD	8	329	784	.37, 7%	R	1.48	0.94-2.33	.09
RPD vs OPD	5	221	577	<.01, 76%	R	1.30	0.32-5.34	.71

F=fixed, DGE=delayed gastric emptying, LPD=laparoscopic pancreatoduodenectomy, MIPD=minimally invasive pancreatoduodenectomy, OPD=open pancreatoduodenectomy, POPF=postoperative pancreatic fistula, R=random, RPD=robot-assisted pancreatoduodenectomy,.

significant difference in terms of major complications between the MIPD and OPD groups (OR = 0.96, 95% CI: 0.76–1.20, P=.70; heterogeneity: I^2 =0%, P=.69) (Fig. 3). The pooled data also showed reduced POPF rates in the MIPD group (OR = 0.79, 95% CI: 0.63–0.99, P=.04) without significant heterogeneity (I^2 =9%, P=.35), which was mainly due to the contributions associated with LPD rather than those of RPD (Fig. 4); in contrast, there was no significant difference between the incidences of clinically significant POPFs (OR=1.02, 95% CI: 0.81–1.30, P=.85; heterogeneity: I^2 =8%, P=.36) (Fig. 5). The

pooled data additionally showed a significant difference with respect to DGE that favored MIPD, which was also mainly due to LPD (OR = 0.71, 95% CI: 0.52–0.96, P=.02; heterogeneity: I^2 = 0%, P=.97) (Fig. 6), and also indicated that those patients who underwent MIPD suffered less in terms of wound infection (OR = 0.56, 95% CI: 0.39–0.79, P < .01) without significant heterogeneity (I^2 =0%, P=.46) (Fig. 7). Lastly, our meta-analysis showed there was no statistically significant difference in the incidences of PPH, reoperation rate, and mortality between the 2 groups (Table 3).

	MIPD)	OPD)		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
2.2.1 LPD vs. OPD								
Asbun	25	53	138	215	12.9%	0.50 [0.27, 0.91]	2012	
Wellner	35	40	33	40	1.8%	1.48 [0.43, 5.14]	2014	
Croome	36	108	107	214	21.4%	0.50 [0.31, 0.81]	2014	
Song	26	97	54	198	11.6%	0.98 [0.56, 1.69]	2015	
Dokmak	34	46	27	46	3.1%	1.99 [0.83, 4.82]	2015	
Delitto	22	52	38	50	10.0%	0.23 [0.10, 0.54]	2016	
Palanivelu	8	32	10	32	3.3%	0.73 [0.25, 2.19]	2017	
Chapman	5	22	7	25	2.3%	0.76 [0.20, 2.85]	2018	
Chen XM	10	47	15	55	4.9%	0.72 [0.29, 1.80]	2018	
Subtotal (95% CI)		497		875	71.2%	0.67 [0.52, 0.85]		•
Total events	201		429					1.427
Heterogeneity: Chi ² = 1	17.67, df =	8 (P =	0.02); l ²	= 55%				
		•						
Test for overall effect:	Z = 3.27 (F	P = 0.00	01)					
Test for overall effect:	Z = 3.27 (F	P = 0.00	D1)					
Test for overall effect: 2	Z = 3.27 (F	^D = 0.00	01)					
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda	Z = 3.27 (F 9	P = 0.00	13	30	4.1%	0.56 [0.19, 1.62]	2012	
Test for overall effect: 2.2.2 RPD vs. OPD Chalikonda Bao	Z = 3.27 (F 9 17	2 = 0.00 30 28	13 26	30 28	4.1% 4.6%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60]	2012 2014	·
Test for overall effect: 2.2.2 RPD vs. OPD Chalikonda Bao Chen S	Z = 3.27 (F 9 17 21	2 = 0.00 30 28 60	13 26 48	30 28 120	4.1% 4.6% 9.3%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54]	2012 2014 2015	·
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto	Z = 3.27 (F 9 17 21 61	30 28 60 83	13 26 48 28	30 28 120 38	4.1% 4.6% 9.3% 4.5%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37]	2012 2014 2015 2016	·
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim	Z = 3.27 (F 9 17 21 61 8	30 28 60 83 51	13 26 48 28 39	30 28 120 38 186	4.1% 4.6% 9.3% 4.5% 6.3%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61]	2012 2014 2015 2016 2018	·
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI)	Z = 3.27 (F 9 17 21 61 8	28 60 83 51 252	13 26 48 28 39	30 28 120 38 186 402	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events	Z = 3.27 (F 9 17 21 61 8 116	30 28 60 83 51 252	13 26 48 28 39 154	30 28 120 38 186 402	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	• • • • • • • • • • • • • • • • • • •
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5	Z = 3.27 (F 9 17 21 61 8 116 5.56, df = 4	30 28 60 83 51 252 4 (P = 0	01) 13 26 48 28 39 154 0.23); ² =	30 28 120 38 186 402 28%	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	•
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2	Z = 3.27 (F 9 17 21 61 8 116 5.56, df = 4 Z = 2.03 (F	30 28 60 83 51 252 4 (P = 0 P = 0.04	13 26 48 28 39 154 0.23); I ² =	30 28 120 38 186 402 28%	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	•
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 Total (95% CI)	Z = 3.27 (F 9 17 21 61 8 116 5.56, df = 4 Z = 2.03 (F	2 = 0.00 30 28 60 83 51 252 4 (P = 0 2 = 0.04 749	13 26 48 28 39 154 0.23); I ² =	30 28 120 38 186 402 28%	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 Total (95% CI) Total events	Z = 3.27 (F 9 17 21 61 8 116 5.56, df = 4 Z = 2.03 (F 317	30 28 60 83 51 252 4 (P = 0 P = 0.04 749	13 26 48 28 39 154 0.23); I ² = 4) 583	30 28 120 38 186 402 28% 1277	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	•
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Total (95% CI) Total events Heterogeneity: Chi ² = 2	Z = 3.27 (F 9 17 21 61 8 116 5.56, df = 4 Z = 2.03 (F 317 23.24, df =	30 28 60 83 51 252 4 (P = 0 P = 0.04 749	13 26 48 28 39 154 0.23); I ² = 4) 583 = 0.04); F	30 28 120 38 186 402 28% 1277 2 = 44%	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	
Test for overall effect: 2 2.2.2 RPD vs. OPD Chalikonda Bao Chen S Delitto Kim Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Total (95% CI) Total events Heterogeneity: Chi ² = 2 Total (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: 2	Z = 3.27 (F 9 17 21 61 8 116 5.56, df = 4 Z = 2.03 (F 317 23.24, df = Z = 3.85 (F	P = 0.00 30 28 60 83 51 252 4 (P = 0 P = 0.00 749 13 (P = 0.00)	13 26 48 28 39 154 0.23); I ² = 4) 583 = 0.04); F 001)	30 28 120 38 186 402 28% 1277 ² = 44%	4.1% 4.6% 9.3% 4.5% 6.3% 28.8%	0.56 [0.19, 1.62] 0.12 [0.02, 0.60] 0.81 [0.42, 1.54] 0.99 [0.41, 2.37] 0.70 [0.30, 1.61] 0.67 [0.45, 0.99]	2012 2014 2015 2016 2018	• • • • • • • • • • • • • • • • • • •

	MIPE	0	OPD)		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed. 95% Cl	Year	M-H. Fixed, 95% CI
2.3.1 LPD vs. OPD								
Asbun	13	53	53	215	10.2%	0.99 [0.49, 2.00]	2012	
Wellner	10	40	7	40	3.4%	1.57 [0.53, 4.65]	2014	
Croome	6	108	29	214	11.8%	0.38 [0.15, 0.93]	2014	
Dokmak	13	46	9	46	4.2%	1.62 [0.61, 4.28]	2015	
Song	8	97	14	198	5.4%	1.18 [0.48, 2.92]	2015	
Delitto	14	52	16	50	7.7%	0.78 [0.33, 1.84]	2016	
Palanivelu	3	32	4	32	2.3%	0.72 [0.15, 3.53]	2017	
Chen XM	1	47	3	55	1.7%	0.38 [0.04, 3.75]	2018	
Meng	9	58	9	58	4.9%	1.00 [0.37, 2.73]	2018	
Subtotal (95% CI)		533		908	51.7%	0.90 [0.65, 1.23]		•
Total events	77		144					
Heterogeneity: Chi ² =	7.16, df =	8 (P = 0).52); l ² =	0%				
Test for overall effect:	Z = 0.67 (P = 0.5	0)					
2.3.2 RPD vs. OPD								
Chen S	7	60	16	120	6.1%	0.86 [0.33, 2.21]	2015	
Boggi	15	83	4	36	2.9%	1.76 [0.54, 5.74]	2016	
Zureikat	50	211	195	817	39.3%	0.99 [0.69, 1.41]	2016	+
Subtotal (95% CI)		354		973	48.3%	1.02 [0.74, 1.40]		•
Total events	72		215					
Heterogeneity: Chi ² =	0.98, df = :	2(P = 0)	0.61); l ² =	0%				
Test for overall effect:	Z = 0.13 (P = 0.9	0)					
Total (95% CI)		887		1881	100.0%	0.96 [0.76, 1.20]		•
Total events	149		359					
Heterogeneity: Chi ² =	8.29, df =	11 (P =	0.69); l ²	= 0%			-	
Test for overall effect:	Z = 0.39 (P = 0.7	0)					0.05 0.2 1 5 20
Test for subaroup diffe	erences: C	$hi^2 = 0.$	32 df = 1	(P = 0,	57). $l^2 = 0^4$	%		Favours MIPD Favours OPD

Figure 3. Forest plot of the meta-analysis: major complications. CI = confidence interval, LPD = laparoscopic pancreatoduodenectomy, MIPD = minimally invasive pancreatoduodenectomy, OPD = open pancreatoduodenectomy, RPD = robot-assisted pancreatoduodenectomy.

	MIPE)	OPD)		Odds Ratio				Odd	ds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	<u> </u>		M-H, Fi	xed, 95	% CI	
.4.1 LPD vs. OPD													
Asbun	7	53	29	215	6.0%	0.98 [0.40, 2.37]	2012			-	1		
Vellner	7	40	11	40	5.5%	0.56 [0.19, 1.63]	2014				-		
Croome	12	108	26	214	9.4%	0.90 [0.44, 1.87]	2014			-	•		
Song	29	97	86	198	24.1%	0.56 [0.33, 0.93]	2015			-	-		
Dokmak	22	46	19	46	6.0%	1.30 [0.57, 2.97]	2015						
Delitto	9	52	18	50	9.2%	0.37 [0.15, 0.94]	2016		19				
Palanivelu	5	32	6	32	3.1%	0.80 [0.22, 2.95]	2017				-		
Aeng	32	58	34	58	9.3%	0.87 [0.42, 1.81]	2018				-		
Chapman	8	22	7	25	2.5%	1.47 [0.43, 5.04]	2018			-	-		
Chen XM	7	47	9	55	4.3%	0.89 [0.31, 2.62]	2018		0				
Subtotal (95% CI)		555		933	79.5%	0.76 [0.58, 0.98]				-			
otal events	138		245										
est for overall effect:	Z = 2.08 (I	P = 0.0	4)	141									
Test for overall effect:	Z = 2.08 (I	P = 0.0	4)										
est for overall effect: .4.2 RPD vs. OPD Chalikonda	Z = 2.08 (I	P = 0.0	4) 5	30	2.6%	0.77 [0.19, 3.20]	2012					_	
Test for overall effect: 2.4.2 RPD vs. OPD Chalikonda	Z = 2.08 (I	P = 0.0 30 28	4) 5 10	30 28	2.6% 4.3%	0.77 [0.19, 3.20]	2012 2014			;			
rest for overall effect: 2.4.2 RPD vs. OPD Chalikonda Bao Chen S	Z = 2.08 (I	P = 0.0 30 28 60	4) 5 10 29	30 28 120	2.6% 4.3% 10.2%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13]	2012 2014 2015					_	
rest for overall effect: 2.4.2 RPD vs. OPD Chalikonda Bao Chen S Boggi	Z = 2.08 (I 4 8 8 28	30 28 60 83	4) 5 10 29 6	30 28 120 36	2.6% 4.3% 10.2% 3.4%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83]	2012 2014 2015 2016				-	-	
rest for overall effect: 2.4.2 RPD vs. OPD Chalikonda Sao Chen S Boggi Subtotal (95% CI)	Z = 2.08 (I 4 8 8 28	30 28 60 83 201	4) 5 10 29 6	30 28 120 36 214	2.6% 4.3% 10.2% 3.4% 20.5 %	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48]	2012 2014 2015 2016					-	
rest for overall effect: 2.4.2 RPD vs. OPD Chalikonda Bao Chen S Boggi Subtotal (95% CI) Total events	Z = 2.08 (1 4 8 28 28 48	30 28 60 83 201	4) 5 10 29 6 50	30 28 120 36 214	2.6% 4.3% 10.2% 3.4% 20.5%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48]	2012 2014 2015 2016					-	
rest for overall effect: 2.4.2 RPD vs. OPD Chalikonda Bao Chen S Boggi Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1	Z = 2.08 (I 4 8 28 48 6.50, df = 3	30 28 60 83 201 3 (P = 0	4) 5 10 29 6 50 0.09); ² =	30 28 120 36 214 54%	2.6% 4.3% 10.2% 3.4% 20.5 %	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48]	2012 2014 2015 2016				•	-	
rest for overall effect: 2.4.2 RPD vs. OPD Chalikonda Bao Chen S Boggi Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Fest for overall effect:	Z = 2.08 (1 4 8 28 48 6.50, df = 3 Z = 0.39 (1	30 28 60 83 201 3 (P = (P = 0.7	4) 5 10 29 6 50 0.09); l ² = 0)	30 28 120 36 214 54%	2.6% 4.3% 10.2% 3.4% 20.5%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48]	2012 2014 2015 2016		-		•	-	
Test for overall effect: 2.4.2 RPD vs. OPD Chalikonda Bao Chen S Boggi Subtotal (95% CI) Total events Heterogeneity: Chi ² = (Test for overall effect: Total (95% CI)	Z = 2.08 (l 4 8 8 28 48 6.50, df = 3 Z = 0.39 (l	30 28 60 83 201 3 (P = 0 P = 0.7 756	5 10 29 6 50 0.09); I ² = 0)	30 28 120 36 214 54%	2.6% 4.3% 10.2% 3.4% 20.5%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48] 0.79 [0.63, 0.99]	2012 2014 2015 2016					-	
est for overall effect: .4.2 RPD vs. OPD Chalikonda tao Chen S loggi subtotal (95% CI) total events leterogeneity: Chi ² = 1 est for overall effect: Total (95% CI) total events	Z = 2.08 (1 4 8 28 48 6.50, df = 3 Z = 0.39 (1 186	30 28 60 83 201 3 (P = 0 P = 0.7 756	4) 5 10 29 6 50 0.09); I ² = 0) 295	30 28 120 36 214 54%	2.6% 4.3% 10.2% 3.4% 20.5%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48] 0.79 [0.63, 0.99]	2012 2014 2015 2016		Ξ				
est for overall effect: .4.2 RPD vs. OPD Chalikonda lao Chen S loggi lubtotal (95% CI) otal events leterogeneity: Chi ² = est for overall effect: otal (95% CI) otal events leterogeneity: Chi ² =	Z = 2.08 (I 4 8 28 48 6.50, df = 3 Z = 0.39 (I 186 14.30, df =	30 28 60 83 201 3 (P = (P = 0.7 756 : 13 (P	4) 5 10 29 6 50 0.09); I ² = 0) 295 = 0.35); I ¹	30 28 120 36 214 54% 1147 * = 9%	2.6% 4.3% 10.2% 3.4% 20.5%	0.77 [0.19, 3.20] 0.72 [0.23, 2.22] 0.48 [0.21, 1.13] 2.55 [0.95, 6.83] 0.91 [0.56, 1.48] 0.79 [0.63, 0.99]	2012 2014 2015 2016	+				-	 +10

Figure 4. Forest plot of the meta-analysis: overall postoperative pancreatic fistula. CI = confidence interval, LPD = laparoscopic pancreatoduodenectomy, MIPD = minimally invasive pancreatoduodenectomy, OPD = open pancreatoduodenectomy, RPD = robot-assisted pancreatoduodenectomy.

	MIPE	0	OPD)		Odds Ratio			Ode	ds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95% C	Year		M-H, F	xed. 95% CI	
2.5.1 LPD vs. OPD											
Asbun	4	53	15	215	4.2%	1.09 [0.35, 3.42]	2012				
Wellner	7	40	11	40	6.9%	0.56 [0.19, 1.63]	2014				
Croome	12	108	26	214	11.8%	0.90 [0.44, 1.87]	2014		8	-	
Dokmak	20	46	15	46	6.4%	1.59 [0.68, 3.71]	2015		-		
Song	6	97	15	198	7.0%	0.80 [0.30, 2.14]	2015				
Delitto	6	52	13	50	8.9%	0.37 [0.13, 1.07]	2016			+	
Palanivelu	2	32	4	32	2.9%	0.47 [0.08, 2.75]	2017	_			
Chapman	8	22	7	25	3.2%	1.47 [0.43, 5.04]	2018				•
Meng	8	58	8	58	5.2%	1.00 [0.35, 2.87]	2018			+	
Chen XM	1	47	1	55	0.7%	1.17 [0.07, 19.30]	2018	_	1		
Subtotal (95% CI)		555		933	57.2%	0.88 [0.63, 1.23]			•	•	
Total events	74		115								
Heterogeneity: Chi ² =	6.53, df = 9	9 (P = (0.69); l ² =	0%							
Test for overall effect:	Z = 0.76 (I	P = 0.4	5)								
2.5.2 RPD vs. OPD											
Chalikonda	4	30	5	30	3.3%	0.77 [0.19, 3.20]	2012			+	
Bao	6	28	6	28	3.6%	1.00 [0.28, 3.58]	2014		-	+	
Chen S	5	60	18	120	8.4%	0.52 [0.18, 1.46]	2015			+	
Boggi	15	83	2	36	1.7%	3.75 [0.81, 17.35]	2016			+	
Zureikat	29	211	74	817	19.9%	1.60 [1.01, 2.53]	2016				
Kim	3	51	19	186	5.9%	0.55 [0.16, 1.94]	2018				
Subtotal (95% CI)		463		1217	42.8%	1.22 [0.86, 1.72]				-	
Total events	62		124								
Heterogeneity: Chi ² =	8.07, df =	5 (P = 0	0.15); l ² =	38%							
Test for overall effect:	Z = 1.11 (I	P = 0.2	7)								
Total (95% CI)		1018		2150	100.0%	1.02 [0.81, 1.30]				•	
Total events	136		239								
Heterogeneity: Chi ² =	16.38, df =	= 15 (P	= 0.36); 1	² = 8%				+		-	+
Test for overall effect:	Z = 0.19 (P = 0.8	5)					0.05	0.2		5 2
Test for subaroup diffe	rences: C	$hi^2 = 0$	76 df = 1	(P = 0)	17), $ ^2 = 4$	3.2%			Favours MIP	D Pavours OF	.0

Figure 5. Forest plot of the meta-analysis: clinically significant postoperative pancreatic fistula. CI=confidence interval, LPD=laparoscopic pancreatoduodenectomy, MIPD=minimally invasive pancreatoduodenectomy, OPD=open pancreatoduodenectomy, RPD=robot-assisted pancreatoduodenectomy.

3.2.3. Oncologic clearance. The pooled data with respect to the RLNs showed that there was an increase in RLN associated with MIPD compared to OPD (WMD=1.85, 95% CI: 1.33–2.37, P < .01). Moreover, the pooled data indicated a comparable R0 rate between the groups (OR = 1.05, 95% CI: 0.79–1.40, P = 0.74). There was no definitive statistically significant result with respect to between-study heterogeneity in RLN (I^2 =42%, P=.12); however, statistically significant between-study heterogeneity was identified in the R0 rate (I^2 =63%, P < .12).

3.3. Publication bias

Funnel plots were drawn for each outcome and subsequently assessed for symmetry. The funnel plots of the publications in this study were found to be symmetrical, which suggested limited or no publication bias (Fig. 8).

4. Discussion

Our meta-analysis revealed that significant reductions in intraoperative blood loss, frequency rate of transfusion, length of hospital stay, and the incidences of overall POPF, DGE, and wound infection were observed after MIPD; the postoperative mortality, major complications, significant POPF, incidences of PPH, reoperation rate, and R0 rate were comparable to the OPD group data; and a prolonged operation time as well as an increase in RLNs were observed in the patients with MIPD. These findings are not in line with those of several previously conducted metaanalyses^[8–12]; however, the present study was conducted including the RCT and only high-quality NRCTs, as well as a comprehensive investigation of the short-term outcomes. We believe the results from our meta-analysis highlight the safety and efficacy of MIPD more robustly than any other publication has to date.

The most important concern regarding the development of any new surgical approach is that of the patient's safety. While previous meta-analyses on the overall postoperative morbidity after MIPD have shown conflicting results, in the present analysis, the overall complication rate was lower for MIPD than OPD, despite the moderate heterogeneity among the included studies ($I^2 = 44\%$). However, the pooled data here indicated no difference in major morbidity, and similarly, our meta-analysis revealed that the overall POPFs after MIPD were fewer, whereas clinically significant POPFs were comparable to that of OPD. Thus, MIPD may be beneficial in reducing minor complications and grade A POPFs when compared to OPD. POPFs are widely regarded as the most common and ominous complications to occur following pancreatic resection, and a significant POPF is the greatest contributor to the major morbidity and mortality that occurs following PD.^[69] A high-quality pancreatic anastomosis would firmly protect patients from the occurrence of severe POPFs, and as such, various surgical procedures have been

	MIP	D	OPD)		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
2.6.1 LPD vs. OPD								
Asbun	6	53	32	215	10.7%	0.73 [0.29, 1.85]	2012	
Croome	10	108	39	214	22.7%	0.46 [0.22, 0.96]	2014	
Wellner	5	40	11	40	9.2%	0.38 [0.12, 1.21]	2014	
Song	3	97	12	198	7.3%	0.49 [0.14, 1.80]	2015	· · · · · · · · · · · · · · · · · · ·
Dokmak	8	46	7	46	5.5%	1.17 [0.39, 3.55]	2015	
Palanivelu	5	32	7	32	5.6%	0.66 [0.19, 2.36]	2017	
Meng	9	58	9	58	7.3%	1.00 [0.37, 2.73]	2018	
Chen XM	2	47	2	55	1.7%	1.18 [0.16, 8.70]	2018	· · · · · · · · · · · · · · · · · · ·
Chapman	6	22	8	25	5.2%	0.80 [0.23, 2.81]	2018	
Subtotal (95% CI)		503		883	75.1%	0.65 [0.46, 0.93]		•
Total events	54		127					
Heterogeneity: Chi ² =	4.18, df =	8 (P = ().84); l ² =	0%				
Test for overall effect:	Z = 2.37 (P = 0.0	2)					
2.6.2 OPD vs. OPD								
Chalikonda	1	30	1	30	0.9%	1.00 [0.06, 16.76]	2012	
Bao	4	28	4	28	3.3%	1.00 [0.22, 4.47]	2014	
Chen S	5	60	18	210	7.0%	0.97 [0.34, 2.73]	2015	
Boggi	46	83	22	36	13.1%	0.79 [0.36, 1.76]	2016	
Kim	0	51	1	186	0.6%	1.20 [0.05, 29.91]	2018	
Subtotal (95% CI)		252		490	24.9%	0.89 [0.51, 1.56]		
Total events	56		46					
Heterogeneity: Chi ² =	0.17. df =	4 (P =	1.00); l ² =	0%				
Test for overall effect:	Z = 0.42 (P = 0.6	8)					
Total (95% CI)		755		1373	100.0%	0.71 [0.52, 0.96]		•
Total events	110		173					
Heterogeneity: Chi ² =	5.11, df =	13 (P =	0.97); l ²	= 0%				
Test for overall effect:	Z = 2.25 (P = 0.0	2)	1000 C				0.05 0.2 1 5 20
Toot for subgroup diffe	ronooo: C	hi2 _ 0	01 df _ 1	/P - 0	00) 12 00			Favours MIPD Favours OPD

Figure 6. Forest plot of the meta-analysis: delayed gastric emptying. CI=confidence interval, LPD=laparoscopic pancreatoduodenectomy, MIPD=minimally invasive pancreatoduodenectomy, OPD=open pancreatoduodenectomy, RPD=robot-assisted pancreatoduodenectomy.

devised to aid in their prevention. Although there have been debates on which procedure (e.g., pancreaticojejunostomy or pancreaticogastrostomy, duct-to-mucosa or invagination anastomosis, and so on) is optimal, they can all be meticulously performed by minimally invasive methods.^[7] Since the true risk factors of significant POPFs (such as soft pancreatic parenchyma, high-risk disease pathology, and small pancreatic duct size) have been recognized.^[70] the comparably severe POPFs rates can be explained, as the high-quality studies included in this metaanalysis have a convincing baseline characteristic comparability. Grade A fistulas are transient and asymptomatic, and have elevated drain amylase levels. The possible reasons for lowering a fistula from grade A in MIPD can be explained as follows: intraoperative high-resolution images help to meticulously separate and protect the pancreatic parenchyma; MIPD has less of an influence on the peripheral organs and peritoneum, leading to the reduced occurrence of seroperitoneum; and the effect of drainage is better in the minimally invasive groups.

The DGEs are the 2nd most common postoperative complications to occur after PD. Although not a life-threatening complication, it delays oral intake, prolongs the hospital stay, diminishes nutritional status, decreases the quality of life, and increases the total costs of hospitalization.^[71] Our pooled data revealed that DGE occurred at a lesser rate in the MIPD than in the OPD group without statistical heterogeneity. The potential reasons for this advantage of MIPD are mainly attributed to the use of a high-solution laparoscope and the meticulous attention to technique, which involves: alleviation of gastric dysrhythmias due to fewer minor POPFs and ascites; ameliorative pyloric or antral ischemia due to the reservation of small vessels; and mitigant pylorospasm secondary to the denervation of the stomach and duodenum or jejunum.

Nevertheless, a reduction in minor POPFs and DGEs does not tell the complete story of fewer overall complications after MIPD. As one of the most complex procedures in abdominal surgery, PD involves multiple organ systems and is likely to cause more medical complications than other similar operations. It is well known that major abdominal surgery has a detrimental effect on respiratory function, particularly with upper abdominal surgery. MIS, however, reduces the risk of such pulmonary complications with its associated mild postoperative pain and the opportunity for earlier ambulation.^[72] Additionally, a lower wound infection rate of MIPD was observed in our meta-analysis, possibly due to the shorter wound length associated with MIPD, and consequently, the incidence rate of postoperative hernia occurring may be less common than that of OPD. Since postoperative hernias usually occur after a long period postsurgery, and the follow-up time in many of the original studies may not have been adequately long, some researchers might not have observed this complication during the course of their research, and thus, only 1 study was found to have documented an incisional hernia.^[56] These findings of comparable major complications and significant POPFs were in accordance with the similar mortality and reoperation data observed in MIPD compared to OPD. The low reported mortality rate could be considered to be an indicator of the safety of this technique.

	MIPE)	OPD)		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	Year	M-H, Fixed, 95% Cl
2.8.1 LPD vs. OPD								a familia da compañía de la compañía
Asbun	6	53	45	215	16.5%	0.48 [0.19, 1.20]	2012	
Delitto	8	52	17	50	15.4%	0.35 [0.14, 0.92]	2016	
Palanivelu	2	32	5	32	4.9%	0.36 [0.06, 2.01]	2017	
Chapman	2	22	7	25	6.2%	0.26 [0.05, 1.40]	2018	
Chen XM	0	47	2	55	2.4%	0.23 [0.01, 4.81]	2018	
Subtotal (95% CI)		206		377	45.4%	0.38 [0.22, 0.67]		• • •
Total events	18		76					
Heterogeneity: Chi ² = 0).61, df = 4	4 (P = (0.96); l ² =	0%				
Test for overall effect: 2	Z = 3.31 (I	P = 0.0	009)					
2.8.2 RPD vs. OPD								
Chalikonda	1	30	1	30	1.0%	1.00 [0.06, 16.76]	2012	
Chen S	1	60	15	120	10.3%	0.12 [0.02, 0.92]	2015	
Zureikat	24	211	109	817	41.5%	0.83 [0.52, 1.33]	2016	
Kim	1	51	4	186	1.8%	0.91 [0.10, 8.32]	2018	
Subtotal (95% CI)		352		1153	54.6%	0.70 [0.46, 1.09]		•
Total events	27		129					
Heterogeneity: Chi ² = 3	8.51, df = 3	3 (P = (0.32); l ² =	14%				
Test for overall effect: 2	Z = 1.57 (I	P = 0.1	2)					
Total (95% CI)		558		1530	100.0%	0.56 [0.39, 0.79]		•
Total events	45		205			A Descharge and the second		
Heterogeneity: Chi ² = 7	7.72, df = 8	8 (P = (0.46); l ² =	0%				
Test for overall effect: 2	Z = 3.30 (I	P = 0.0	010)					0.01 0.1 1 10 100
Test for subaroup diffe	rences: C	$hi^2 = 2$.	81 df = 1	(P = 0,	$(09), 1^2 = 64$	4.4%		Favours MIPD Favours OPD

Figure 7. Forest plot of the meta-analysis: wound infection. Cl=confidence interval, LPD=laparoscopic pancreatoduodenectomy, MIPD=minimally invasive pancreatoduodenectomy, OPD=open pancreatoduodenectomy, RPD=robot-assisted pancreatoduodenectomy.



Figure 8. Funnel plots of the meta-analysis: (A) operative time, (B) blood loss, (C) hospital stay, (D) morbidity, (E) major complications, (F) postoperative pancreatic fistula (POPF), (G) significant POPF, (H) delayed gastric emptying, (I) mortality.

In line with previous meta-analyses, a longer operative time and less blood loss were observed in MIPD. Although none of the MIPD studies identified any adverse outcomes, a recent study from the American College of Surgeons NSQIP demonstrated that longer operative times were independently associated with worse perioperative outcomes after pancreatic resection.^[73] Since a longer duration of surgery might also indicate intraoperative difficulties or surgical inexperience, those surgeons who wish to embark on an MIPD program should have a clear plan, including the recruitment of trained providers and/or training of the local team as well as avoiding complex cases (such as obese patients, neoadjuvant treatment, preoperative biliary stenting, vascular involvement, and/or concurrent organ resections) during the learning curve.^[7,73]

The time required for postoperative recovery has been reported in only a few of the studies, precluding the meta-analysis. Two studies here reported significantly faster returns to ambulation and bowel recovery following MIPD compared to OPD.^[59,67] In line with previous meta-analyses, a shorter hospital stay was also observed for patients with MIPD, with fewer complications, reduced pain and use of analgesic drugs,^[49,61,67] sound nutritional status,^[59] and earlier activities all contributing to shorten the hospital stay.

The role of MIPD in the setting of malignancy is currently under evaluation, and thus, good quality reproducible data on this is limited. Several studies have reported disease free and/or overall survival with comparable or favorable outcomes with MIPD as compared to OPD^[57,59,61,63,65,67]; however, the different malignancies among various patients, short-term assessment, and lack of other data to precisely validate these findings prompts the need for further studies. The majority of published studies instead focus on the surrogates of an oncologic resection, namely lymph node retrieval and surgical margin status. Our analysis revealed that MIPD was associated with an increase in RLNs and comparable R0 resection rates. The removal of a sufficient number of lymph nodes could enhance the accuracy of staging and regional disease control. The advantages of high-resolution images, multidimensional vision, and meticulous manipulation could help MIPD facilitate lymphadenectomy. However, the increase in lymph node retrieval associated with the MIPD group should be interpreted with caution; consideration of a selection bias is important, as easy-to-surgery patients are being chosen for the novel technique. Furthermore, different pathologic processing techniques of the surgical specimen have also been shown to yield significantly different lymph node counts.^[74] Another potential advantage of MIPD here may be the earlier receipt of adjuvant chemotherapy thanks to the shorter hospital stay, but definitive evidence would still be needed for this. Based on a similar theory, major complications could negatively impact the survival of patients undergoing curative-intent pancreatectomy, as morbidity influences multimodality therapy completion.^[75] We cannot conclusively confirm whether MIPD has such aforementioned advantages, since major complications were also similarly identified from our pooled data. Thus, the paucity of data with respect to oncologic outcomes in MIPD underscores the need for careful and prospective scrutiny with regards to the longterm outcomes.

Our study assesses the surgical outcomes of patients undergoing PD, comparing the results of the minimally invasive approach to the open approach. The methodologic advantages of this metaanalysis include that it firstly evaluated the quality of all potential studies, and only then did it proceed to these methodologic highquality comparative studies for further evaluation, nine of which

were also case-matched studies.^[53,55,56,58-61,63,67] This study provides the highest possible level of evidence despite the shortage of RCTs. On the contrary, the results of this metaanalysis should also be interpreted with caution due to its several limitations, which are as follows. Firstly, the significant heterogeneity among the different studies regarding several parameters subjects our results to potential bias. There was inevitably a selection bias in the published literature, as the baseline characteristics of the patients and the indications for operative procedures in the 2 groups were not fully equal in all studies, tending to favor MIPD. Moreover, a total of 16 studies were included in our meta-analysis, with almost half of them originating from the United States (7 studies). This information implies that a publication bias possibly exists in our study. Another potential source of a publication bias is associated with the articles that were not published publicly. Secondly, clinical heterogeneity associated with our meta-analysis requires attention. The surgical techniques performed were variable in both the OPD and MIPD groups. Other factors include diverse areas, different diseases, varied severity among patients, and so on, and additionally, some endpoints have different measurements (e.g., blood loss) and not all of the articles used the Clavien-Dindo classification of surgical complications.[55,56,65] Thirdly, the minimally invasive arms used, especially those of robotic cohorts, in most if not all of these institutions represent their initial surgical experiences, which could subsequently introduce another bias against the MIPD outcomes. Contrarily, it should be emphasized that most of the studies should originate from experts and pioneering centers, resulting in better outcomes for this specialization in pancreatic surgery.^[76] Thus, the conclusions drawn here may not be feasible to implement in smaller centers. Conclusively, methodologic high-quality RCTs using standardized reporting of outcomes are required and strongly encouraged.

5. Conclusion

This study suggests that MIPD is a safe alternative to OPD, as it is associated with less blood loss and better postoperative recovery in terms of a shorter hospital stay and fewer overall postoperative complications. However, this technique also has a longer operative time compared to the open procedure. Although a thorough evaluation of the short-term and long-term oncologic outcomes of MIPD was not possible here, the rate of margin positivity and number of RLNs were either comparable to, or even better than those observed in OPD. Improved levels of evidence, standardized reporting of outcomes, and ensuring the inclusion of proper RCTs in the meta-analysis are the next challenges that face this promising technique.

Author contributions

Conceptualization: Jia-fei Yan. Data curation: Yu Pan. Formal analysis: Jia-fei Yan. Funding acquisition: Qi-long Chen. Investigation: Ke Chen, He-pan Zhu. Methodology: Jia-fei Yan, Qi-long Chen. Resources: He-pan Zhu. Software: Yu Pan. Supervision: Qi-long Chen. Writing – original draft: Jia-fei Yan. Writing – review & editing: Qi-long Chen.

References

- Kneuertz PJ, Pitt HA, Bilimoria KY, et al. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg 2012;16:1727–35.
- [2] Gawande A. Two hundred years of surgery. N Engl J Med 2012;366:1716–23.
- [3] Chen K, Pan Y, Zhai ST, et al. Totally laparoscopic versus open total gastrectomy for gastric cancer: a case-matched study about short-term outcomes. Medicine 2017;96:e8061.
- [4] Chen K, Pan Y, Zhang B, et al. Laparoscopic versus open pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and metaanalysis. Int J Surg 2018;53:243–56.
- [5] Chen K, Zhang B, Liang YL, et al. Laparoscopic versus open resection of small bowel gastrointestinal stromal tumors: systematic review and meta-analysis. Chin Med J 2017;130:1595–603.
- [6] Magge D, Zureikat A, Hogg M, et al. Minimally invasive approaches to pancreatic surgery. Surg Oncol Clin N Am 2016;25:273–86.
- [7] Kendrick ML, van Hilst J, Boggi U, et al. Minimally invasive pancreatoduodenectomy. HPB (Oxford) 2017;19:215–24.
- [8] Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, et al. Minimallyinvasive vs open pancreaticoduodenectomy: systematic review and metaanalysis. J Am Coll Surg 2014;218:129–39.
- [9] de Rooij T, Lu MZ, Steen MW, et al. Minimally invasive versus open pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and registry studies. Ann Surg 2016;264:257–67.
- [10] Peng L, Lin S, Li Y, et al. Systematic review and meta-analysis of robotic versus open pancreaticoduodenectomy. Surg Endosc 2017;31:3085–97.
- [11] Zhang H, Wu X, Zhu F, et al. Systematic review and meta-analysis of minimally invasive versus open approach for pancreaticoduodenectomy. Surg Endosc 2016;30:5173–84.
- [12] Pedziwiatr M, Malczak P, Pisarska M, et al. Minimally invasive versus open pancreatoduodenectomy-systematic review and meta-analysis. Langenbecks Arch Surg 2017;402:841–51.
- [13] MacLehose RR, Reeves BC, Harvey IM, et al. A systematic review of comparisons of effect sizes derived from randomised and nonrandomised studies. Health Technol Assess 2000;4:1–54.
- [14] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
- [15] Slim K, Nini E, Forestier D, et al. Methodological index for nonrandomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–6.
- [16] Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8–13.
- [17] Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142:761–8.
- [18] Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007;142:20–5.
- [19] Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187–96.
- [20] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
- [21] Cho A, Yamamoto H, Nagata M, et al. Comparison of laparoscopyassisted and open pylorus-preserving pancreaticoduodenectomy for periampullary disease. Am J Surg 2009;198:445–9.
- [22] Buchs NC, Addeo P, Bianco FM, et al. Robotic versus open pancreaticoduodenectomy: a comparative study at a single institution. World J Surg 2011;35:2739–46.
- [23] Zhou NX, Chen JZ, Liu Q, et al. Outcomes of pancreatoduodenectomy with robotic surgery versus open surgery. Int J Med Robot 2011;7:131–7.
- [24] Zureikat AH, Breaux JA, Steel JL, et al. Can laparoscopic pancreaticoduodenectomy be safely implemented? J Gastrointest Surg 2011;15:1151–7.
- [25] Kuroki T, Adachi T, Okamoto T, et al. A non-randomized comparative study of laparoscopy-assisted pancreaticoduodenectomy and open pancreaticoduodenectomy. Hepatogastroenterology 2012;59:570–3.
- [26] Lai EC, Yang GP, Tang CN. Robot-assisted laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy–a comparative study. Int J Surg 2012;10:475–9.

- [27] Lei Z, Zhifei W, Jun X, et al. Pancreaticojejunostomy sleeve reconstruction after pancreaticoduodenectomy in laparoscopic and open surgery. JSLS 2013;17:68–73.
- [28] Hakeem AR, Verbeke CS, Cairns A, et al. A matched-pair analysis of laparoscopic versus open pancreaticoduodenectomy: oncological outcomes using Leeds Pathology Protocol. Hepatobiliary Pancreat Dis Int 2014;13:435–41.
- [29] Langan RC, Graham JA, Chin AB, et al. Laparoscopic-assisted versus open pancreaticoduodenectomy: early favorable physical quality-of-life measures. Surgery 2014;156:379–84.
- [30] Speicher PJ, Nussbaum DP, White RR, et al. Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. Ann Surg Oncol 2014;21:4014–9.
- [31] Wang Y, Bergman S, Piedimonte S, et al. Bridging the gap between open and minimally invasive pancreaticoduodenectomy: the hybrid approach. Can J Surg 2014;57:263–70.
- [32] Adam MA, Choudhury K, Dinan MA, et al. Minimally invasive versus open pancreaticoduodenectomy for cancer: practice patterns and shortterm outcomes among 7061 patients. Ann Surg 2015;262:372–7.
- [33] Croome KP, Farnell MB, Que FG, et al. Pancreaticoduodenectomy with major vascular resection: a comparison of laparoscopic versus open approaches. J Gastrointest Surg 2015;19:189–94.
- [34] Liang S, Jayaraman S. Getting started with minimally invasive pancreaticoduodenectomy: is it worth it? J Laparoendosc Adv Surg Tech A 2015;25:712–9.
- [35] Mendoza AS3rd, Han HS, Yoon YS, et al. Laparoscopy-assisted pancreaticoduodenectomy as minimally invasive surgery for periampullary tumors: a comparison of short-term clinical outcomes of laparoscopy-assisted pancreaticoduodenectomy and open pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2015;22:819–24.
- [36] Sharpe SM, Talamonti MS, Wang CE, et al. Early national experience with laparoscopic pancreaticoduodenectomy for ductal adenocarcinoma: a comparison of laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy from the national cancer data base. J Am Coll Surg 2015;221:175–84.
- [37] Baker EH, Ross SW, Seshadri R, et al. Robotic pancreaticoduodenectomy: comparison of complications and cost to the open approach. Int J Med Robot 2016;12:554–60.
- [38] Nussbaum DP, Adam MA, Youngwirth LM, et al. Minimally invasive pancreaticoduodenectomy does not improve use or time to initiation of adjuvant chemotherapy for patients with pancreatic adenocarcinoma. Ann Surg Oncol 2016;23:1026–33.
- [39] Tran TB, Dua MM, Worhunsky DJ, et al. The first decade of laparoscopic pancreaticoduodenectomy in the United States: costs and outcomes using the nationwide inpatient sample. Surg Endosc 2016;30:1778–83.
- [40] Chapman BC, Gajdos C, Hosokawa P, et al. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Surg Endosc 2018;32:2239–48.
- [41] Conrad C, Basso V, Passot G, et al. Comparable long-term oncologic outcomes of laparoscopic versus open pancreaticoduodenectomy for adenocarcinoma: a propensity score weighting analysis. Surg Endosc 2017;31:3970–8.
- [42] Kantor O, Talamonti MS, Sharpe S, et al. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. Am J Surg 2017;213:512–5.
- [43] McMillan MT, Zureikat AH, Hogg ME, et al. A propensity scorematched analysis of robotic vs open pancreatoduodenectomy on incidence of pancreatic fistula. JAMA Surg 2017;152:327–35.
- [44] Poves I, Morato O, Burdio F, et al. Laparoscopic-adapted Blumgart pancreaticojejunostomy in laparoscopic pancreaticoduodenectomy. Surg Endosc 2017;31:2837–45.
- [45] Stauffer JA, Coppola A, Villacreses D, et al. Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Surg Endosc 2017;31:2233–41.
- [46] Khaled YS, Fatania K, Barrie J, et al. Matched case-control comparative study of laparoscopic versus open pancreaticoduodenectomy for malignant lesions. Surg Laparosc Endosc Percutan Tech 2018;28:47–51.
- [47] Kantor O, Pitt HA, Talamonti MS, et al. Minimally invasive pancreatoduodenectomy: is the incidence of clinically relevant postoperative pancreatic fistula comparable to that after open pancreatoduodenectomy? Surgery 2018;163:587–93.

12

- [48] Mesleh MG, Stauffer JA, Bowers SP, et al. Cost analysis of open and laparoscopic pancreaticoduodenectomy: a single institution comparison. Surg Endosc 2013;27:4518–23.
- [49] Tan CL, Zhang H, Peng B, et al. Outcome and costs of laparoscopic pancreaticoduodenectomy during the initial learning curve vs laparotomy. World J Gastroenterol 2015;21:5311–9.
- [50] Tee MC, Croome KP, Shubert CR, et al. Laparoscopic pancreatoduodenectomy does not completely mitigate increased perioperative risks in elderly patients. HPB (Oxford) 2015;17:909–18.
- [51] Girgis MD, Zenati MS, Steve J, et al. Robotic approach mitigates perioperative morbidity in obese patients following pancreaticoduodenectomy. HPB (Oxford) 2017;19:93–8.
- [52] Napoli N, Kauffmann EF, Menonna F, et al. Robotic versus open pancreatoduodenectomy: a propensity score-matched analysis based on factors predictive of postoperative pancreatic fistula. Surg Endosc 2018;32:1234–47.
- [53] Palanivelu C, Senthilnathan P, Sabnis SC, et al. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. Br J Surg 2017;104:1443–50.
- [54] Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the Accordion Severity Grading System. J Am Coll Surg 2012;215:810–9.
- [55] Chalikonda S, Aguilar-Saavedra JR, Walsh RM. Laparoscopic roboticassisted pancreaticoduodenectomy: a case-matched comparison with open resection. Surg Endosc 2012;26:2397–402.
- [56] Bao PQ, Mazirka PO, Watkins KT. Retrospective comparison of robotassisted minimally invasive versus open pancreaticoduodenectomy for periampullary neoplasms. J Gastrointest Surg 2014;18:682–9.
- [57] Croome KP, Farnell MB, Que FG, et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014;260:633–8.
- [58] Wellner UF, Kusters S, Sick O, et al. Hybrid laparoscopic versus open pylorus-preserving pancreatoduodenectomy: retrospective matched case comparison in 80 patients. Langenbecks Arch Surg 2014;399:849–56.
- [59] Chen S, Chen JZ, Zhan Q, et al. Robot-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. Surg Endosc 2015;29:3698–711.
- [60] Dokmak S, Fteriche FS, Aussilhou B, et al. Laparoscopic pancreaticoduodenectomy should not be routine for resection of periampullary tumors. J Am Coll Surg 2015;220:831–8.
- [61] Song KB, Kim SC, Hwang DW, et al. Matched case-control analysis comparing laparoscopic and open pylorus-preserving pancreaticoduodenectomy in patients with periampullary tumors. Ann Surg 2015;262:146–55.
- [62] Boggi U, Napoli N, Costa F, et al. Robotic-assisted pancreatic resections. World J Surg 2016;40:2497–506.
- [63] Delitto D, Luckhurst CM, Black BS, et al. Oncologic and perioperative outcomes following selective application of laparoscopic pancreatico-

duodenectomy for periampullary malignancies. J Gastrointest Surg 2016;20:1343–9.

- [64] Zureikat AH, Postlewait LM, Liu Y, et al. A multi-institutional comparison of perioperative outcomes of robotic and open pancreaticoduodenectomy. Ann Surg 2016;264:640–9.
- [65] Chapman BC, Gleisner A, Ibrahim-Zada I, et al. Laparoscopic pancreaticoduodenectomy: changing the management of ampullary neoplasms. Surg Endosc 2018;32:915–22.
- [66] Kim HS, Han Y, Kang JS, et al. Comparison of surgical outcomes between open and robot-assisted minimally invasive pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2018;25:142–9.
- [67] Meng LW, Cai YQ, Li YB, et al. Comparison of laparoscopic and open pancreaticoduodenectomy for the treatment of nonpancreatic periampullary adenocarcinomas. Surg Laparosc Endosc Percutan Tech 2018;28:56–61.
- [68] Chen XM, Sun DL, Zhang Y. Laparoscopic versus open pancreaticoduodenectomy combined with uncinated process approach: a comparative study evaluating perioperative outcomes (retrospective cohort study). Int J Surg 2018;51:170–3.
- [69] Pratt WB, Maithel SK, Vanounou T, et al. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 2007;245:443–51.
- [70] Callery MP, Pratt WB, Kent TS, et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg 2013;216:1–4.
- [71] Akizuki E, Kimura Y, Nobuoka T, et al. Reconsideration of postoperative oral intake tolerance after pancreaticoduodenectomy: prospective consecutive analysis of delayed gastric emptying according to the ISGPS definition and the amount of dietary intake. Ann Surg 2009;249:986–94.
- [72] Fuks D, Cauchy F, Fteriche S, et al. Laparoscopy decreases pulmonary complications in patients undergoing major liver resection: a propensity score analysis. Ann Surg 2016;263:353–61.
- [73] Maggino L, Liu JB, Ecker BL, et al. Impact of operative time on outcomes after pancreatic resection: a risk-adjusted analysis using the American College of Surgeons NSQIP Database. J Am Coll Surg 2018;226:844–57.
- [74] Adsay NV, Basturk O, Altinel D, et al. The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment. Mod Pathol 2009;22:107–12.
- [75] Le AT, Huang B, Hnoosh D, et al. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. J Surg Res 2017;214:1–8.
- [76] Ahola R, Siiki A, Vasama K, et al. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma. Br J Surg 2017;104:1532–8.